Apogee Therapeutics' second quarter of 2026 is a finance footnote stapled to a deal document. On June 18, AbbVie agreed to acquire every share of the clinical-stage immunology company for $135.11 per share in cash, a 53% premium to the $88.43 undisturbed close on June 17 and a 63% premium to the 30-day volume-weighted average through that date, putting the deal at an aggregate equity value of roughly $10.9 billion and an enterprise value near $9.7 billion after backing out $1.3 billion of cash and marketable securities and adding the $99.2 million revenue-share liability owed to Blackstone Life Sciences. The transaction is in the regulatory-clearance window, not a hypothetical: the HSR waiting period expired on August 5, German Federal Cartel Office unconditional clearance landed the same week, the Austrian Phase 1 review closed on August 4, the Australian Competition and Consumer Commission phase-one window runs through September 7, and the special meeting on August 11 delivered a 99.96% vote in favor of adoption on 46.5 million shares cast. The deal is expected to close in the third quarter of 2026, before the December 18, 2026 initial outside date, with an automatic six-month extension to June 18, 2027 if non-regulatory conditions remain the only unfinished items, and a Parent-only discretionary extension to December 18, 2027 beyond that.
Apogee's stock is no longer pricing the company - it is pricing the probability the deal closes. Shares traded at $134.55 on the August 12 close, a $0.56 spread below the cash consideration, or roughly +0.4% to the deal price, and have held in a tight band of $134.02 to $134.88 since the proxy mailing on July 14. That pricing is the merger-arb quote: a deal in which the buyer has delivered financing certainty (no financing condition; AbbVie guarantees Parent's obligations), the target has already cleared the most material voting hurdle, and the remaining items are antitrust phase-one completions and customary closing deliveries. The $4.4 million of merger transaction costs charged in the quarter, the same headline that does not matter for valuation, sits in a quarter that does not matter for the trade. The Q2 pipeline news underneath - positive 16-week Part B APEX induction data supporting the planned Phase 3 dose, the ELEVATE EoE Phase 2a launch and ASPIRE asthma Phase 2b launch timetable, the Blackstone Life Sciences up to $1.3 billion revenue-participation facility - all matter only because they are the diligence evidence already in the buyer's hands.
The thesis for anyone long the equity at $134.55 is straightforward: capture the $0.56 spread in roughly four to sixteen weeks while the remaining antitrust phase-one windows close, then exit into the cash merger. The bear case is a deal-break: a non-US regulator finds the IL-13 / immunology overlap substantial enough to demand divestitures, an unexpected material adverse effect emerges in the interim, or the Australia or another EU jurisdiction opens a Phase 2 review that pushes the close past the initial outside date. The 3.50% reverse-termination fee of $381.3 million that AbbVie's Parent would owe Apogee in a deal-break scenario is the floor under the worst-case reversion value, sitting at roughly $1.5 billion of net cash plus a Phase 3-ready zumilokibart pipeline that AbbVie's most aggressive peer set values at a meaningful independent multiple. At a 0.4% spread, the deal is being priced as effectively certain to close; the residual risk is the small chance of the unexpected.